Novel antiglaucoma prodrugs and codrugs of ethacrynic acid.
The purpose of this study was to synthesize a novel prodrug of ethacrynic acid (ECA) with short chain polyethylene glycols (PEGs) and codrugs of ECA with the beta-adrenergic blocking agent atenolol (ATL) or timolol (TML) to overcome the adverse effects of ECA and to enhance its physicochemical properties.
New England Eye Center, Boston, MA 02111, USA.
Grazyna
G
Cynkowska
Tadeusz
T
Cynkowski
Abeer M
AM
Al-Ghananeem
Abeer A
AA
Al-Ghananeem
Hong
H
Guo
Paul
P
Ashton
Peter A
PA
Crooks
D000319:Adrenergic beta-Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D001262:Atenolol / Q000494:pharmacology; D004976:Ethacrynic Acid / Q000009:adverse effects / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000737:chemistry; D011355:Prodrugs / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D013999:Timolol / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D011355:Prodrugs; D011092:Polyethylene Glycols; D001262:Atenolol; D013999:Timolol; D004976:Ethacrynic Acid